Skip to main content
Erschienen in: World Journal of Urology 4/2014

01.08.2014 | Original Article

18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer

verfasst von: H. Kjölhede, G. Ahlgren, H. Almquist, F. Liedberg, K. Lyttkens, T. Ohlsson, O. Bratt

Erschienen in: World Journal of Urology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare 18F-fluorocholine positron-emission tomography/computed tomography (PET/CT) with extended pelvic lymph node dissection (ePLND) for the detection of lymph node metastases in a large cohort of patients with high-risk prostate cancer.

Materials and methods

Patients with prostate-specific antigen levels between 20 and 99 ng/mL and/or Gleason score 8–10 cancers, planned for treatment with curative intent following a negative or inconclusive standard bone scan, were investigated with 18F-fluorocholine PET/CT followed by an ePLND. None of the patients received hormonal therapy prior to these staging procedures. Results for PET/CT were compared on a per-patient basis with histopathology from ePLND. Sensitivity, specificity, positive and negative predictive values were calculated.

Results

PET/CT detected a total of 76 suspected lymph node metastases and four suspected bone metastases in 33 (29 %) of the 112 included patients. Of these, 35 suspected lymph node metastases, only within the anatomical template area of an ePLND, were found in 21 of the patients. Histopathology of the ePLND specimens detected 117 lymph node metastases in 48 (43 %) of the 112 patients. Per-patient sensitivity, specificity, positive and negative predictive values for 18F-fluorocholine PET/CT for lymph node metastases within the ePLND template were 0.33, 0.92, 0.76 and 0.65, respectively. Only 11 patients had lymph nodes larger than 10 mm that would have been reported by CT alone.

Conclusions

18F-fluorocholine PET/CT detects lymph node metastases in a significant proportion of patients with high-risk prostate cancer with a high specificity, but low sensitivity.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71PubMedCrossRef Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61–71PubMedCrossRef
2.
Zurück zum Zitat Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52(1):29–37PubMedCrossRef Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52(1):29–37PubMedCrossRef
3.
Zurück zum Zitat Hövels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395PubMedCrossRef Hövels AM, Heesakkers RAM, Adang EM, Jager GJ, Strum S, Hoogeveen YL et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63(4):387–395PubMedCrossRef
4.
Zurück zum Zitat Heesakkers RA, Hövels AM, Jager GJ, Van Den Bosch HC, Witjes JA, Raat HP et al (2008) MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 9(9):850–856PubMedCrossRef Heesakkers RA, Hövels AM, Jager GJ, Van Den Bosch HC, Witjes JA, Raat HP et al (2008) MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 9(9):850–856PubMedCrossRef
5.
Zurück zum Zitat Giannarini G, Petralia G, Thoeny HC (2012) Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 61(2):326–340PubMedCrossRef Giannarini G, Petralia G, Thoeny HC (2012) Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 61(2):326–340PubMedCrossRef
6.
Zurück zum Zitat Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD (2002) Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate cancer prostatic dis 5(2):132–135PubMedCrossRef Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD (2002) Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate cancer prostatic dis 5(2):132–135PubMedCrossRef
7.
Zurück zum Zitat Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen W-D, Brelin A et al (2011) Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys 81(1):29–34PubMedCrossRef Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen W-D, Brelin A et al (2011) Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys 81(1):29–34PubMedCrossRef
8.
Zurück zum Zitat Häcker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W et al (2006) Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 176(5):2014–2018 (discussion 2018–2019)PubMedCrossRef Häcker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W et al (2006) Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 176(5):2014–2018 (discussion 2018–2019)PubMedCrossRef
9.
Zurück zum Zitat Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF et al (2010) [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer 46(2):449–455PubMedCrossRef Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF et al (2010) [F(18)]-fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer 46(2):449–455PubMedCrossRef
10.
Zurück zum Zitat Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F et al (2010) 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254(3):925–933PubMedCrossRef Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F et al (2010) 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254(3):925–933PubMedCrossRef
11.
Zurück zum Zitat De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44(3):331–335PubMed De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 44(3):331–335PubMed
12.
Zurück zum Zitat Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A et al (2008) Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35(2):253–263PubMedCrossRef Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A et al (2008) Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35(2):253–263PubMedCrossRef
13.
Zurück zum Zitat Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N, et al. (2010) [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 106:639–643; discussion 644 Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N, et al. (2010) [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 106:639–643; discussion 644
14.
Zurück zum Zitat Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A et al (2008) 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54(2):392–401PubMedCrossRef Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A et al (2008) 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54(2):392–401PubMedCrossRef
15.
Zurück zum Zitat Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T et al (2012) Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 110(10):1501–1506PubMedCrossRef Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T et al (2012) Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 110(10):1501–1506PubMedCrossRef
16.
Zurück zum Zitat Kryza D, Tadino V, Filannino MA, Villeret G, Lemoucheux L (2008) Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer. Nucl Med Biol 35(2):255–260PubMedCrossRef Kryza D, Tadino V, Filannino MA, Villeret G, Lemoucheux L (2008) Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer. Nucl Med Biol 35(2):255–260PubMedCrossRef
17.
Zurück zum Zitat Schillaci O, Calabria F, Tavolozza M, Cicciò C, Carlani M, Caracciolo CR et al (2010) 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 31(1):39–45PubMedCrossRef Schillaci O, Calabria F, Tavolozza M, Cicciò C, Carlani M, Caracciolo CR et al (2010) 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 31(1):39–45PubMedCrossRef
18.
Zurück zum Zitat Gil-Vernet JM (1996) Prostate cancer: anatomical and surgical considerations. Br J Urol 78(2):161–168PubMedCrossRef Gil-Vernet JM (1996) Prostate cancer: anatomical and surgical considerations. Br J Urol 78(2):161–168PubMedCrossRef
19.
Zurück zum Zitat Meijer HJM, van Lin EN, Debats O a, Witjes JA, Span PN, Kaanders JH a M et al (2011) High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 82(4):1405–1410 Meijer HJM, van Lin EN, Debats O a, Witjes JA, Span PN, Kaanders JH a M et al (2011) High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 82(4):1405–1410
20.
Zurück zum Zitat Mattei A, Fuechsel FG, Bhatta Dhar N, Warncke SH, Thalmann GN, Krause T et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53(1):118–125PubMedCrossRef Mattei A, Fuechsel FG, Bhatta Dhar N, Warncke SH, Thalmann GN, Krause T et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53(1):118–125PubMedCrossRef
21.
Zurück zum Zitat Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R (2001) Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166(5):1715–1719PubMedCrossRef Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R (2001) Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166(5):1715–1719PubMedCrossRef
22.
Zurück zum Zitat Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate—to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048PubMedCrossRef Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate—to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048PubMedCrossRef
23.
Zurück zum Zitat Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S et al (2011) Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol 29(5):595–605PubMedCrossRef Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S et al (2011) Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol 29(5):595–605PubMedCrossRef
Metadaten
Titel
18F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer
verfasst von
H. Kjölhede
G. Ahlgren
H. Almquist
F. Liedberg
K. Lyttkens
T. Ohlsson
O. Bratt
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2014
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-013-1189-x

Weitere Artikel der Ausgabe 4/2014

World Journal of Urology 4/2014 Zur Ausgabe

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.